Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies (Details)

Commitments and Contingencies (Details)					1 Months Ended			3 Months Ended	12 Months Ended		16 Months Ended	39 Months Ended
Commitments and Contingencies (Details)	Apr. 01, 2021 USD ($)	Feb. 03, 2020 USD ($) milestone	Sep. 24, 2018 USD ($) therapy milestone	Feb. 16, 2018 unit $ / shares	Aug. 31, 2019 USD ($)	Jul. 31, 2019 USD ($)	Aug. 31, 2017 USD ($)	Dec. 31, 2020	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Apr. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)
Operating Leased Assets [Line Items]
Revenues									$ 6,698,615	$ 6,750,351
Potential future regulatory milestone							$ 20,000,000.0
Royalty agreement, payment received						$ 2,000,000
Period after public launch to terminate agreement						3 years
Buyout option, percentage of net present value of royalty payments						75.00%
Aevi
Operating Leased Assets [Line Items]
Payment for contingent consideration									0
Aevi
Operating Leased Assets [Line Items]
Contingent consideration		$ 6,500,000
Number of contingent consideration milestones \| milestone		2
Aevi \| Milestone One
Operating Leased Assets [Line Items]
Contingent consideration		$ 2,000,000.0
Aevi \| Milestone Two
Operating Leased Assets [Line Items]
Contingent consideration		$ 4,500,000
Ichorion
Operating Leased Assets [Line Items]
Contingent consideration			$ 15,000,000.0
Number of contingent consideration milestones \| milestone			3
Payment for contingent consideration									0
Scenario, Forecast \| Ichorion \| Milestone One
Operating Leased Assets [Line Items]
Payment for contingent consideration												$ 6,000,000.0
Scenario, Forecast \| Ichorion \| Milestone Two
Operating Leased Assets [Line Items]
Payment for contingent consideration												5,000,000.0
Scenario, Forecast \| Ichorion \| Milestone Three
Operating Leased Assets [Line Items]
Payment for contingent consideration												$ 4,000,000.0
Millipred \| Teva Pharmaceutical Industries Ltd.
Operating Leased Assets [Line Items]
Extended term								30 months
Millipred \| Scenario, Forecast \| Teva Pharmaceutical Industries Ltd.
Operating Leased Assets [Line Items]
Semi-annual payment											$ 75,000
Percent of net profit for installment payments	50.00%
Installment payments	$ 500,000
CERC-611
Operating Leased Assets [Line Items]
Potential milestone payment					$ 7,500,000
Potential milestone revenue threshold					750,000,000.0
Potential milestone payment two					12,500,000
Potential milestone revenue threshold two					1,300,000,000
Potential milestone revenue threshold two					$ 1,300,000
CERC-611 \| Armistice
Operating Leased Assets [Line Items]
Revenue from related parties									100,000
License and other revenue
Operating Leased Assets [Line Items]
Revenues							$ 25,000,000.0		$ 0	$ 100,000
CERC-801, CERC-802, And CERC-803 \| Ichorion
Operating Leased Assets [Line Items]
Number of preclinical therapies \| therapy			3
CERC-913 \| Ichorion
Operating Leased Assets [Line Items]
Number of preclinical therapies \| therapy			1
TRIS Pharma \| Karbinal Agreement
Operating Leased Assets [Line Items]
Minimum quantity required \| unit				70,000
Make whole payment per unit (in dollars per share) \| $ / shares				$ 30